**Study Overview**: This study is testing a new treatment, EYP-1901, for **wet Age-Related Macular Degeneration** (wAMD), a condition where the eye's retina gets damaged, causing vision loss. It's a **Phase 3 trial**, which means the treatment has already been tested for safety and is now being studied for effectiveness. The study compares EYP-1901 to another treatment called **Aflibercept**.
**Eligibility**: To join, participants should have wAMD and meet specific vision requirements. Participants can be new to treatment or have received certain eye injections before. People with severe eye damage or very low vision in the other eye cannot participate.
**Key Points**:
- **Duration**: The study lasts for 2 years, with main results at week 56.
- **Participation**: Involves regular doctor visits and eye check-ups.
- **Risks/Compensation**: Discuss with the study team; details on potential compensation and risks will be provided.
This study helps find better treatments for wAMD, potentially improving vision for many people. If you think you might be eligible, talk to your eye doctor for more information.
How understandable was the trial content above?
Hard to understand
Easy to understand